After a review of clinical data from the Generation Program studies, Novartis, Amgen and Banner Alzheimer’s Institute have decided to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase II/III studies in the Alzheimer’s Prevention Initiative Generation Program.